196 related articles for article (PubMed ID: 15801868)
21. An evaluation of the pharmacokinetics and pharmacodynamics of the histrelin implant for the palliative treatment of prostate cancer.
Dineen MK; Tierney DS; Kuzma P; Pentikis HS
J Clin Pharmacol; 2005 Nov; 45(11):1245-9. PubMed ID: 16239357
[TBL] [Abstract][Full Text] [Related]
22. Random luteinizing hormone often remains pubertal in children treated with the histrelin implant for central precocious puberty.
Lewis KA; Eugster EA
J Pediatr; 2013 Mar; 162(3):562-5. PubMed ID: 23040793
[TBL] [Abstract][Full Text] [Related]
23. Exisulind: Aptosyn, FGN 1, Prevatac, sulindac sulfone.
Drugs R D; 2004; 5(4):220-6. PubMed ID: 15230629
[TBL] [Abstract][Full Text] [Related]
24. Histrelin. A review of its pharmacological properties and therapeutic role in central precocious puberty.
Barradell LB; McTavish D
Drugs; 1993 Apr; 45(4):570-88. PubMed ID: 7684676
[TBL] [Abstract][Full Text] [Related]
25. Rubitecan: 9-NC, 9-Nitro-20(S)-camptothecin, 9-nitro-camptothecin, 9-nitrocamptothecin, RFS 2000, RFS2000.
Drugs R D; 2004; 5(5):305-11. PubMed ID: 15357630
[TBL] [Abstract][Full Text] [Related]
26. Treatment patterns, health resource utilization and costs among central precocious puberty patients treated with leuprolide or histrelin: an examination of the commercial and Medicaid populations.
Klein KO; Soliman AM; Bonafede M; Nelson JK; Grubb E
J Med Econ; 2020 Apr; 23(4):407-414. PubMed ID: 31766907
[No Abstract] [Full Text] [Related]
27. Satraplatin: BMS 182751, BMY 45594, JM 216.
Drugs R D; 2007; 8(2):125-32. PubMed ID: 17324011
[TBL] [Abstract][Full Text] [Related]
28. Efaproxiral: GSJ 61, JP 4, KDD 86, RS 4, RSR 13.
Drugs R D; 2005; 6(3):178-85. PubMed ID: 15869322
[TBL] [Abstract][Full Text] [Related]
29. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
[TBL] [Abstract][Full Text] [Related]
30. Intraoperative sonographic localization of a fractured Supprelin implant in a pediatric patient: a case report.
Monroe BJ; Fallon SC; Brandt ML
J Pediatr Endocrinol Metab; 2012; 25(1-2):167-9. PubMed ID: 22570970
[TBL] [Abstract][Full Text] [Related]
31. Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3.
Drugs R D; 2005; 6(2):120-7. PubMed ID: 15777106
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of histrelin subdermal implant in patients with advanced prostate cancer.
Schlegel PN;
J Urol; 2006 Apr; 175(4):1353-8. PubMed ID: 16515997
[TBL] [Abstract][Full Text] [Related]
33. Cancer vaccine THERATOPE- Biomira.
Adis International Ltd
Drugs R D; 2003; 4(4):236-40. PubMed ID: 12848588
[TBL] [Abstract][Full Text] [Related]
34. Surgical and anesthetic considerations in histrelin capsule implantation for the treatment of precocious puberty.
Davis JS; Alkhoury F; Burnweit C
J Pediatr Surg; 2014 May; 49(5):807-10. PubMed ID: 24851775
[TBL] [Abstract][Full Text] [Related]
35. Trends in the use of puberty blockers among transgender children in the United States.
Lopez CM; Solomon D; Boulware SD; Christison-Lagay ER
J Pediatr Endocrinol Metab; 2018 Jun; 31(6):665-670. PubMed ID: 29715194
[TBL] [Abstract][Full Text] [Related]
36. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
[TBL] [Abstract][Full Text] [Related]
37. Reversibility of androgen deprivation therapy in patients with prostate cancer.
Fridmans A; Chertin B; Koulikov D; Lindenberg T; Gelber H; Leiter C; Farkas A; Spitz IM
J Urol; 2005 Mar; 173(3):784-9. PubMed ID: 15711270
[TBL] [Abstract][Full Text] [Related]
38. Mismatched double-stranded RNA: polyI:polyC12U.
Adis Editorial
Drugs R D; 2004; 5(5):297-304. PubMed ID: 15357629
[TBL] [Abstract][Full Text] [Related]
39. Methylnaltrexone: MNTX.
Drugs R D; 2006; 7(6):374-8. PubMed ID: 17073520
[TBL] [Abstract][Full Text] [Related]
40. Optimizing pediatric histrelin implantation to improve success rates in clinic without sedation.
Krishna V; Lee SL; DeUgarte DA
J Pediatr Endocrinol Metab; 2021 Nov; 34(11):1443-1448. PubMed ID: 34407329
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]